Articles tagged with Angiogenesis
Wayne State University has secured a $1.9 million NIH grant to study the role of chemokine receptor CXCR2 in regulating new blood vessel formation and enhancing endothelial progenitor cells (EPCs)-based cell therapy for vascular diseases.
Rice University researchers created a detailed model of cell signaling in blood vessels that feed tumors. The study found that jagged ligands play a major role in the chaotic vessel growth observed around tumors, suggesting that suppressing notch-jagged signaling may disrupt tumor angiogenesis.
A study found that electro-acupuncture at Conception and Governor vessels, combined with mesenchymal stem cell transplantation, promotes neurological function recovery and angiogenesis in rats after cerebral ischemia/reperfusion. The researchers concluded that the combination has synergistic effects on promoting angiogenesis and recove...
Researchers found that hypoxic preconditioning reduced infarct volume and impaired neurological function in a mouse model of cerebral infarction. Increased vascular endothelial growth factor and CD31 expression promoted angiogenesis, leading to improved outcomes.
A study led by Boston University School of Medicine researchers reveals that methylation signaling regulates VEGFR-2, leading to angiogenesis and tumor growth. This finding provides a promising new approach to blocking cancer growth by targeting this biochemical process.
Combining certain foods like tomatoes, broccoli, and olive oil may enhance their antiangiogenesis abilities, research suggests. Developing these food products will require extensive tests in food safety and efficacy.
Researchers at UCL Institute of Ophthalmology identify LRG1 as a protein responsible for abnormal blood vessel growth in diseases like cancer, macular degeneration, and rheumatoid arthritis. Inhibition of LRG1 may be a promising target for future therapy.
Researchers at UC San Diego identified apoA-I binding protein as a key player in regulating blood vessel growth by removing excess cholesterol from endothelial cells. This process inhibits angiogenesis and can help prevent tumor growth.
The novel inhibitor XL-184 (Cabozantinib) showed significant tumor growth decrease in 12 colorectal cancer explants, with 8 exhibiting stable disease. The drug targets both VEGFR2 signaling pathway and c-MET for survival of tumor cells.
Researchers have discovered a potent physiological anti-angiogenic factor, PEDF, that reverses symptoms of endometriosis and ovarian hyperstimulation syndrome without compromising fertility. The injectable protein has shown promising results in pre-clinical studies.
Researchers found that threonyl tRNA synthetase (TARS) plays a critical role in angiogenesis, the formation of new blood vessels, to support cancer growth. A potent inhibitor of TARS activity blocks its induction of angiogenesis.
Scientists found that Ang-2 regulates angiogenesis through TIE-2 and integrin signaling, leading to two independent effects on tumor blood vessels. This discovery prompts the development of new therapies targeting Ang-2.
Research reveals a link between Glyoxylase 1 and increased anxiety in mice, with implications for potential therapeutic targets. Additionally, studies provide hope for new treatments for the rare disease Beare-Stevens syndrome and graft versus host disease.
Researchers at CNIO have discovered a new target for developing anti-angiogenic and anti-tumoral therapies. The protein ephrinB2 was found to play a crucial role in angiogenesis and lymphoangiogenesis, processes that promote tumour growth and metastasis.
A team led by Martin Friedlander at Scripps Research Institute has received a $10.2 million grant to develop a new treatment strategy for diabetic retinopathy, macular degeneration, and other vision disorders. The approach targets a strand of micro-RNA that promotes abnormal blood vessel growth.
Researchers at UNC School of Medicine discovered that the protein Shc plays a vital role in forming new blood vessels through its ability to coordinate signals from growth factors and extracellular matrix. This finding highlights the importance of understanding molecular mechanisms in disease development and treatment.
Researchers discovered a chromatin insulator binding factor CTCF that blocks VEGF activation, regulating angiogenesis and cancer progression. This finding opens a window to manage angiogenesis and cancer using CTCF as a target.
A study published in The American Journal of Pathology reveals a novel mechanism for pillar formation during intussusceptive angiogenesis in tumors. The researchers found that targeting just one type of blood vessel formation may not be sufficient to slow tumor growth, and instead propose a more tailored approach to anti-tumor therapy.
A new molecular imaging agent has been developed to detect tumor angiogenesis, a process of rapid blood vessel growth associated with malignant cancers. The agent, which targets the CD105 protein biomarker, shows promising results in early studies, including high uptake by tumors in mice.
Researchers discovered that injecting DKK2 improved vascular regeneration in a mouse model of myocardial infarction. This suggests potential for pharmacological manipulation to treat various vascular diseases.
A new type of VEGFR-3 blocking antibody has been developed to inhibit angiogenesis in cancerous tumors. The antibody was shown to be effective even at high concentrations of the growth factor, and combining it with another inhibitor provided synergistic inhibition.
Researchers have identified a new target for stopping tumors from developing their own blood supply, with a newly developed drug called ACE-041 showing promising results in advanced cancer patients. The drug targets the ALK-1 receptor and has been shown to halt tumor progression and improve patient outcomes.
Researchers discovered that galectin-3 promotes angiogenesis by binding to specific cell-adhesion proteins, suggesting potential therapeutic targets. Targeting the protein with inhibitors significantly reduced angiogenesis in mice, offering new approaches for treating diseases caused by excessive blood vessel growth.
Researchers found that chronic morphine use decreases levels of tumor angiogenesis, mediated by suppression of signaling induced by low oxygen concentrations. This effect suggests morphine may inhibit tumor growth and serve as an anti-angiogenic agent in cancer pain management.
Researchers developed a non-invasive MRI method to visualize and quantify tumor angiogenesis, a crucial process for cancer growth. The new technique uses nanotechnology and MRI to detect early stages of blood vessel formation, enabling more accurate diagnosis and treatment adjustments.
Researchers found resveratrol inhibits pathogenic new blood vessel growth, a central role in various cancers and eye disease. The compound may offer a novel therapeutic strategy to treat these diseases.
Researchers used NBI to visualize mucosal angiogenesis in IBD patients and found abnormal microvascular changes not seen with white light colonoscopy. This technology may aid in assessing mucosal angiogenesis and could be beneficial for IBD treatment.
Pericytes, contractile cells surrounding capillaries, use mechanical forces to initiate angiogenesis, a crucial process in cancer, diabetic retinopathy, and age-related macular degeneration. The study suggests that local contractions could serve as initiating mechanical signals influencing angiogenesis.
The European Association of Urology Congress highlights advances in renal cell carcinoma management, including immunotherapy, targeted therapies, and angiogenesis blockers. New treatments like bevacizumab, sunitinib, sorafenib, temsirolimus, and everolimus have shown promise in stabilizing metastatic kidney cancer for a certain period.
Researchers discovered that bone marrow cells produce nerve growth factor, which promotes angiogenesis and prevents hypoxia in transplanted islets. The study, led by Dr. Eba Hathout, found a potential role for NGF in islet transplantation and prevention of graft failure.
A preclinical model of human prostate cancer mimics primary tumors' genetic behavior, offering a platform for biomarker and drug discovery. High expression levels of delta-like ligand 4 in breast cancer predict poor prognosis.
Researchers at Karolinska Institutet have identified a new way to block blood vessel formation and halt tumour growth in mice. The discovery focuses on the ALK1 receptor, which is activated by TGF-β proteins that stimulate angiogenesis in tumours.
Scientists discovered that blocking delta-catenin expression disrupts inflammation-induced angiogenesis in tumors and wounds. The findings suggest that delta-catenin may be a key player in cancer progression.
A new study reveals that exercise stimulates the creation of new blood vessels in leg muscles, a process known as angiogenesis, thanks to the PGC-1alpha protein. This finding could lead to new treatments for peripheral artery disease and prevent amputations.
Researchers identified a new mechanism by which HRG protein inhibits angiogenesis and tumor growth in cancer patients. The study shows that the HRG fragment binds to endothelial cells and platelets, creating a microenvironment that functions as an angiogenesis inhibitor.
A probiotic bacterium, Bacillus polyfermenticus, has been shown to effectively treat colitis in mice by promoting the growth of new blood vessels. The study found that the bacteria increased angiogenesis, a process necessary for wound healing, and reduced inflammation in affected tissues.
GS-101 demonstrates significant inhibition and regression of corneal neovascularisation in a phase II study. The treatment is generally well-tolerated with no serious side effects, offering a new approach to managing ophthalmic angiogenesis.
Researchers at Keio University found that matrix metalloproteinases improve wound healing in mice, while a complement inhibitor FUT-175 delays autoimmune disease onset. Additionally, a new target for tumor angiogenesis inhibition and bone morphogenic protein-7 (BMP-7) have been identified as potential therapies for liver high blood pre...
The study found that tumors with strong angiogenesis showed high enhancement in the arterial dominant phase, while those with fibrosis had a negative correlation. Dynamic CT features related to angiogenesis can be modified by intratumoral fibrosis, which may impact treatment with anti-angiogenesis agents.
Researchers at UNC Lineberger Comprehensive Cancer Center found a new protein SFRP2 that stimulates angiogenesis in various tumor sites. The discovery provides a potential target for developing new drugs to starve tumors of blood supply and destroy them.
Researchers at Uppsala University developed a tool to study signals controlling blood vessel growth, enabling scientists to determine what attracts or repels vessels. This knowledge is crucial in tumor research, as unwanted angiogenesis can fuel tumor growth.
This Festschrift issue honors Dr. Judah Folkman's groundbreaking contributions to lymphatic research and biology. Leading scientists share their findings on the impact of his work, including increased lymphatic supply to cancerous lesions and new trends in cancer therapy.
A new role for the protein PrP has been identified in regulating food intake, with mice lacking PrP becoming obese in adulthood. Additionally, a protein FHL1 has been found to help heart muscle cells respond to high pressure, while a protein AIP1 regulates blood vessel formation under inflammatory conditions.
In a phase II trial, pazopanib was found to shrink lung cancer tumors in 30 out of 35 patients by up to 85%. The results suggest that pazopanib is highly active in early stage operable lung cancer. Further development of this drug in lung cancer is underway.
Lodamin, a novel oral angiogenesis inhibitor, has shown promising anticancer results in mice, demonstrating its potential as a preventive therapy for patients at high risk of cancer. The drug selectively accumulates in tumor tissue, blocks angiogenesis, and inhibits primary tumor growth without apparent side effects.
The study introduces HB-19, an experimental synthetic molecule that inhibits both tumor cell growth and angiogenesis. In mice models, HB-19 treatment suppresses tumor development and eliminates measurable tumors without toxicity.
Thrombospondin 1 (TSP-1) expression correlates with the progression of fibrosis and angiogenesis in experimental cirrhosis. The study suggests that TSP-1 may contribute to wound healing response to liver injury by inducing angiogenesis.
Scientists at Dana-Farber Cancer Institute have found an alternate pathway to angiogenesis, triggered by PGC-1alpha sensing low oxygen levels. This discovery may offer new opportunities for treating heart and blood vessel diseases.
New research reveals VEGF-B's protective effects on nerve cells without inducing angiogenesis, providing new hope for treating neurodegenerative diseases. VEGF-B treatment has shown to inhibit brain cell death in mouse models of stroke and ocular neurodegenerative disorders.
Researchers have discovered a protein called CIB1 that plays a major role in controlling new blood vessel growth, providing a potential target for drug therapies. The findings may help control unwanted blood vessel growth in diseases such as diabetic retinopathy and wound healing.
A novel molecular switch controls protein synthesis to promote tumor growth and survival in locally advanced breast cancer. The switch is regulated by two factors, 4E-BP1 and eIF4G, which are strongly over-expressed in human large advanced breast tumors.
Researchers developed a new mouse model to predict the loss of orally taken drugs due to metabolism by CYP3A, a key enzyme involved in first-pass metabolism. The study found that mice lacking functional CYP3A proteins accumulated docetaxol at higher levels, demonstrating the enzyme's role in intestinal metabolism.
Researchers have found that a combination of radiation treatment and angiogenesis inhibitors can overcome tumor radioresistance by inducing apoptosis in tumor cells. This dual therapy approach shows promise in treating tumors resistant to radiation, offering a new potential treatment strategy.
Researchers discovered that cancer cells forming blood vessels exhibit a distinct distribution of cellular copper, which may help explain how copper-reducing cancer therapy works. This finding has implications for understanding the regulation of metal ion content in metal-binding proteins and could lead to new cancer therapies.
Researchers found that African American women are diagnosed with breast cancer at an average age of 46, compared to 57 for white women. The study proposes that the excess mortality occurs partly because black women are more likely to develop breast cancer before menopause, when surgery may pose a higher risk of stimulating cancer growth.
A study published in the Journal of Neuroscience has identified two proteins, SDF1 and Ang1, as key triggers for neuronal migration and regeneration after a stroke. These molecular signals, released by newly formed blood vessels, promote post-stroke neuroblast migration, holding promise for developing new therapies to repair brain cells.
Scientists identified SFLT-1 as the protein responsible for preventing blood vessel growth in corneas. Deactivating this protein allows angiogenesis to occur, leading to conditions such as macular degeneration and cancer. The discovery opens doors to new treatments by harnessing the natural anti-angiogenic properties of the eye.
Researchers at the University of Wisconsin-Madison have discovered a new compound that inhibits angiogenesis, a process essential for tumor growth. The compound, called NK-B, works by preventing the production of vascular endothelial growth factor and reducing receptor molecules that respond to VEGF.
Researchers discovered how Myc oncoprotein drives tumor angiogenesis in pancreatic cancer by inducing IL-1beta expression. Blocking IL-1beta activity can thwart tumor angiogenesis, offering experimental evidence for cancer drug therapies targeting this pathway.
Researchers have made significant breakthroughs in cancer vaccine development and cardiac health. A study on mice vaccinated with mimotopes inducing intermediate magnitude T cell responses found protection against tumor growth, while a study on Casq2-deficient mice revealed the mechanisms behind irregular heartbeats during exercise.